Table 2.

Effects of PPARα-agonists on triglycerides (TG) and high-density lipoprotein-cholesterol (HDL-C) levels

Compound	Aleglitazar	GFT505		K-877	Fenofibrate
Study	SYNCHRONY[43,44]	S1[48]	S2[48]	K-877 P2[50]	FIELD[12]	K-877[50]
Dosage	150 μg QD	80 mg QD	80 mg QD	100 μg BID	200 mg QD	100 mg QD
Time point (weeks)	16	4	4	12	16	12
TG
Baseline (mg/dL)	157.7*	283.5	194.9	290.9	172.8	325.2
Change vs. baseline	NA	−51.4	−62.9	NA	NA	NA
(mg/dL)
% change vs. baseline	−29.7**	NA	NA	−41.4	NA	−30.7
% change vs. placebo	−43.4**	−16.7**	−24.8**	−69.9	−28.6	−59.2
HDL-C
Baseline (mg/dL)	46.8	34.8	46.4	40.9	42.5	40.1
Change vs. baseline	NA	2.7	3.1	NA	NA	NA
(mg/dL)
% change vs. baseline	25.1**	NA	NA	16.9	NA	13.0
% change vs. placebo	20.7**	7.8**	9.3**	18.2	5.1	14.3

BID twice daily; NA, not available; QD once daily;

Where necessary, values were multiplied by 88.6 for TG and by 38.67 for HDL-C to convert from mmol/L to mg/dL.

Values are expressed as means unless otherwise stated.

*Median.

**Least squares means.